Basic Information
| LncRNA/CircRNA Name | EGFR-AS1 |
| Synonyms | NA |
| Region | GRCh38_7:55179750-55188934 |
| Ensemble | ENSG00000224057 |
| Refseq | NR_047551 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | Gefitinib | ||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | squamous cell carcinoma |
| ICD-0-3 | NA |
| Methods | qPCR etc. |
| Sample | cell lines (NCC-NH1, NCC-NH43, NCC-NH73, NCC-NH26, NCC-NH64, NCC-NH119) |
| Expression Pattern | up-regulated |
| Function Description | Remarkably, single-copy G>A nucleotide editing in isogenic models conferred a 70-fold increase in sensitivity due to decreased stability of the EGFR-AS1 long noncoding RNA (lncRNA). In the appropriate context, sensitivity could be recapitulated through EGFR-AS1 knockdown in vitro and in vivo, whereas overexpression was sufficient to induce resistance to TKIs. Reduced EGFR-AS1 levels shifted splicing toward EGFR isoform D, leading to ligand-mediated pathway activation. In co-clinical trials involving patients and patient-derived xenograft (PDX) models, tumor shrinkage was most pronounced in the context of the A/A genotype for EGFR-Q787Q, low expression of EGFR-AS1 and high expression of EGFR isoform D. Our study reveals how a ??ilent??mutation influences the levels of a lncRNA, resulting in noncanonical EGFR addiction, and delineates a new predictive biomarker suite for response to EGFR TKIs. |
| Pubmed ID | 28920960 |
| Year | 2017 |
| Title | Long noncoding RNA EGFR-AS1 mediates epidermal growth factor receptor addiction and modulates treatment response in squamous cell carcinoma |
External Links
| Links for EGFR-AS1 | GenBank HGNC NONCODE |
| Links for squamous cell carcinoma | OMIM COSMIC |